HRP20110044T2 - Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem - Google Patents

Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem Download PDF

Info

Publication number
HRP20110044T2
HRP20110044T2 HR20110044T HRP20110044T HRP20110044T2 HR P20110044 T2 HRP20110044 T2 HR P20110044T2 HR 20110044 T HR20110044 T HR 20110044T HR P20110044 T HRP20110044 T HR P20110044T HR P20110044 T2 HRP20110044 T2 HR P20110044T2
Authority
HR
Croatia
Prior art keywords
alkyl
group
groups
methyl
substituted
Prior art date
Application number
HR20110044T
Other languages
English (en)
Croatian (hr)
Inventor
Wienen Wolfgang
Pfau Roland
Gerlach Kai
Dahmann Georg
Priepke Henning
Nar Herbert
Handschuh Sandra
Schuler-Metz Annette
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20110044T1 publication Critical patent/HRP20110044T1/xx
Publication of HRP20110044T2 publication Critical patent/HRP20110044T2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
HR20110044T 2005-06-30 2011-01-21 Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem HRP20110044T2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014270 2005-06-30
PCT/EP2006/063611 WO2007003536A1 (de) 2005-06-30 2006-06-28 Substituierte glycinamide mit antithrombotischer und faktor xa-inhibierender wirkung

Publications (2)

Publication Number Publication Date
HRP20110044T1 HRP20110044T1 (en) 2011-02-28
HRP20110044T2 true HRP20110044T2 (hr) 2012-02-29

Family

ID=35907001

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110044T HRP20110044T2 (hr) 2005-06-30 2011-01-21 Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem

Country Status (33)

Country Link
US (3) US20100216769A1 (ru)
EP (1) EP1899330B9 (ru)
JP (1) JP4768016B2 (ru)
KR (1) KR101321722B1 (ru)
CN (1) CN101213195B (ru)
AR (1) AR054627A1 (ru)
AT (1) ATE489381T1 (ru)
AU (1) AU2006265216B2 (ru)
BR (1) BRPI0612580A8 (ru)
CA (1) CA2613059C (ru)
CY (1) CY1111627T1 (ru)
DE (1) DE502006008392D1 (ru)
DK (1) DK1899330T3 (ru)
EA (1) EA015188B1 (ru)
EC (1) ECSP078058A (ru)
ES (1) ES2357029T3 (ru)
HK (1) HK1116190A1 (ru)
HR (1) HRP20110044T2 (ru)
IL (1) IL188323A (ru)
MX (1) MX2007016253A (ru)
MY (1) MY145883A (ru)
NO (1) NO340670B1 (ru)
NZ (1) NZ565440A (ru)
PE (1) PE20070171A1 (ru)
PL (1) PL1899330T3 (ru)
PT (1) PT1899330E (ru)
RS (1) RS51572B (ru)
SG (1) SG163540A1 (ru)
SI (1) SI1899330T1 (ru)
TW (1) TWI392495B (ru)
UA (1) UA94910C2 (ru)
WO (1) WO2007003536A1 (ru)
ZA (1) ZA200708525B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006041773A2 (en) 2004-10-04 2006-04-20 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US20090312306A1 (en) * 2006-07-20 2009-12-17 Guangri Sun Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
PE20081834A1 (es) * 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
EP2220079A2 (en) * 2007-11-15 2010-08-25 Boehringer Ingelheim International GmbH Substituted amides, manufacturing and use thereof as medicaments
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
WO2010065134A1 (en) 2008-12-05 2010-06-10 Millennium Pharmaceuticals, Inc. 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors
JP2012517997A (ja) * 2009-02-17 2012-08-09 Msd株式会社 1,4−ベンゾジアゼピン−2−オン誘導体
EP2552479A4 (en) 2010-03-30 2015-03-04 Sinai School Medicine INFLUENZA VIRUS VACCINES AND USES THEREOF
JP6498439B2 (ja) 2011-09-20 2019-04-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
MX2015007755A (es) 2012-12-18 2016-01-14 Icahn School Med Mount Sinai Vacunas contra virus de la influenza y sus usos.
CN108892661B (zh) * 2014-02-07 2023-03-14 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
CR20200640A (es) 2018-07-05 2021-02-15 Bayer Ag Substituted thiophenecarboxamides and analogues as antibacterials agents
CN111196772B (zh) * 2018-11-16 2022-09-30 沈阳化工研究院有限公司 一种芳酰氨基异丁酰衍生物及其应用
MX2022007663A (es) 2019-12-20 2022-07-19 Bayer Ag Tieniloxazolonas y analogos.
US11691960B2 (en) 2020-11-06 2023-07-04 Boehringer Ingelheim International Gmbh 2-[thiophen-2-yl)formamido]-N-(phenyl)-2-methylpropanamide derivatives and the use thereof as medicament

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE303988T1 (de) 1999-06-14 2005-09-15 Lilly Co Eli Inhibitoren von serin proteasen
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1307203A4 (en) 2000-03-21 2005-08-17 Smithkline Beecham Corp PROTEINASE INHIBITOR
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040157828A1 (en) 2001-05-17 2004-08-12 Ren Xie Protease inhibitors
JP2004300133A (ja) * 2002-11-19 2004-10-28 Takeda Chem Ind Ltd アミン誘導体
PE20040837A1 (es) 2002-11-19 2004-12-24 Takeda Chemical Industries Ltd Compuestos de amina
DE10254336A1 (de) 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7250415B2 (en) 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
JP2007537181A (ja) * 2004-05-13 2007-12-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換されたチオフェン−カルボン酸アミド、医薬品の形態におけるこれらの製造及び使用
WO2005111013A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
WO2005111029A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Neue substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE102004047840A1 (de) * 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
PE20081834A1 (es) 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos

Also Published As

Publication number Publication date
HK1116190A1 (en) 2008-12-19
US9676781B2 (en) 2017-06-13
MX2007016253A (es) 2008-03-07
TW200738692A (en) 2007-10-16
ES2357029T3 (es) 2011-04-15
AU2006265216A1 (en) 2007-01-11
DE502006008392D1 (de) 2011-01-05
WO2007003536A1 (de) 2007-01-11
CA2613059C (en) 2013-12-24
EP1899330B9 (de) 2011-11-09
JP2008546741A (ja) 2008-12-25
TWI392495B (zh) 2013-04-11
US20150252050A1 (en) 2015-09-10
RS51572B (en) 2011-08-31
CN101213195B (zh) 2012-05-09
BRPI0612580A8 (pt) 2017-12-26
UA94910C2 (ru) 2011-06-25
IL188323A0 (en) 2008-04-13
EP1899330A1 (de) 2008-03-19
NO340670B1 (no) 2017-05-29
PT1899330E (pt) 2011-01-11
KR20080033318A (ko) 2008-04-16
US9062034B2 (en) 2015-06-23
ECSP078058A (es) 2008-01-23
SG163540A1 (en) 2010-08-30
EA015188B1 (ru) 2011-06-30
PE20070171A1 (es) 2007-03-08
JP4768016B2 (ja) 2011-09-07
US20100216769A1 (en) 2010-08-26
BRPI0612580A2 (pt) 2010-11-23
PL1899330T3 (pl) 2011-05-31
SI1899330T1 (sl) 2011-03-31
KR101321722B1 (ko) 2013-10-25
IL188323A (en) 2013-08-29
NO20075186L (no) 2008-02-14
ATE489381T1 (de) 2010-12-15
CY1111627T1 (el) 2015-10-07
CN101213195A (zh) 2008-07-02
AR054627A1 (es) 2007-07-04
MY145883A (en) 2012-05-15
CA2613059A1 (en) 2007-01-11
NZ565440A (en) 2011-04-29
DK1899330T3 (da) 2011-02-21
AU2006265216B2 (en) 2011-09-29
EA200702620A1 (ru) 2008-06-30
EP1899330B1 (de) 2010-11-24
ZA200708525B (en) 2009-08-26
HRP20110044T1 (en) 2011-02-28
US20130184256A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
HRP20110044T2 (hr) Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem
JP2010522713A5 (ru)
ES2677480T3 (es) Agentes que inducen apoptosis
US8063077B2 (en) Factor Xa inhibitors
JP5558557B2 (ja) C型肝炎ウイルス阻害剤
AR110421A1 (es) Derivados de pirazol como inhibidores de malt1
JP2009537483A5 (ru)
ES2865182T3 (es) Inhibidor de URAT1
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
RU2007133655A (ru) Замещенные бис-арильные и гетероарильные соединения в качестве селективных антагонистов 5нт2а
RU2552533C2 (ru) Противовирусные соединения и их применения
AU2014219855A1 (en) Trk-inhibiting compound
JP2008545686A5 (ru)
AR071386A1 (es) Compuestos heterociclicos nitrogenados, inhibidores carbamato y urea de la 11-beta-hidroxiesteroide deshidrogenasa tipo 1(11 beta-hsd1),composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad,hipertension,trastornos cognitivos y otras enfermedades.
RU2011147233A (ru) Азетидинилдиамиды в качестве ингибиторов моноацилглицерин-липазы
RU2014120373A (ru) Соединения азетидина, композиции и их применение в качестве ингибиторов растворимой эпоксидгидролазы
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20060609A1 (es) Derivados de quinuclidinas como antagonistas del receptor muscarinico (m3)
ES2558608T3 (es) Derivados hetero-bicíclicos como inhibidores del VHC
JP2009532415A5 (ru)
JP2010504286A5 (ru)
AR070797A1 (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes
ES2421896T3 (es) Compuestos de aril-(imidazol)-metil-fenilo sustituidos como moduladores selectivos de los subtipos de receptores adrenérgicos alfa 2B y/o alfa 2C
JP2016527184A5 (ru)
CN106029640A (zh) 吡唑啉酮化合物及其用途